nodes	percent_of_prediction	percent_of_DWPC	metapath
Triflupromazine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.145	0.167	CbGbCtD
Triflupromazine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.132	0.151	CbGbCtD
Triflupromazine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.114	0.131	CbGbCtD
Triflupromazine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.11	0.127	CbGbCtD
Triflupromazine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0997	0.115	CbGbCtD
Triflupromazine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0997	0.115	CbGbCtD
Triflupromazine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0956	0.11	CbGbCtD
Triflupromazine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0739	0.085	CbGbCtD
Triflupromazine—DRD1—nerve—acquired immunodeficiency syndrome	0.0107	0.117	CbGeAlD
Triflupromazine—DRD2—nerve—acquired immunodeficiency syndrome	0.00632	0.0691	CbGeAlD
Triflupromazine—BCHE—blood plasma—acquired immunodeficiency syndrome	0.00434	0.0474	CbGeAlD
Triflupromazine—HTR2B—skin of body—acquired immunodeficiency syndrome	0.00284	0.031	CbGeAlD
Triflupromazine—DRD2—retina—acquired immunodeficiency syndrome	0.00262	0.0286	CbGeAlD
Triflupromazine—DRD1—nervous system—acquired immunodeficiency syndrome	0.00241	0.0263	CbGeAlD
Triflupromazine—DRD1—central nervous system—acquired immunodeficiency syndrome	0.00232	0.0253	CbGeAlD
Triflupromazine—HTR2B—digestive system—acquired immunodeficiency syndrome	0.00227	0.0248	CbGeAlD
Triflupromazine—HTR2B—blood—acquired immunodeficiency syndrome	0.00216	0.0237	CbGeAlD
Triflupromazine—BCHE—skin of body—acquired immunodeficiency syndrome	0.00209	0.0228	CbGeAlD
Triflupromazine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00207	0.0226	CbGeAlD
Triflupromazine—HTR2B—vagina—acquired immunodeficiency syndrome	0.00201	0.0219	CbGeAlD
Triflupromazine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.00194	0.0212	CbGeAlD
Triflupromazine—CHRM1—lung—acquired immunodeficiency syndrome	0.00191	0.0208	CbGeAlD
Triflupromazine—HTR2B—lung—acquired immunodeficiency syndrome	0.0019	0.0207	CbGeAlD
Triflupromazine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.00187	0.0204	CbGeAlD
Triflupromazine—DRD1—brain—acquired immunodeficiency syndrome	0.00184	0.0201	CbGeAlD
Triflupromazine—CHRM1—nervous system—acquired immunodeficiency syndrome	0.00177	0.0193	CbGeAlD
Triflupromazine—HTR2B—nervous system—acquired immunodeficiency syndrome	0.00176	0.0192	CbGeAlD
Triflupromazine—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.0017	0.0186	CbGeAlD
Triflupromazine—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.00169	0.0185	CbGeAlD
Triflupromazine—BCHE—digestive system—acquired immunodeficiency syndrome	0.00167	0.0182	CbGeAlD
Triflupromazine—BCHE—blood—acquired immunodeficiency syndrome	0.00159	0.0174	CbGeAlD
Triflupromazine—BCHE—bone marrow—acquired immunodeficiency syndrome	0.00154	0.0168	CbGeAlD
Triflupromazine—DRD2—lung—acquired immunodeficiency syndrome	0.00154	0.0168	CbGeAlD
Triflupromazine—BCHE—spinal cord—acquired immunodeficiency syndrome	0.00153	0.0167	CbGeAlD
Triflupromazine—CHRM2—brain—acquired immunodeficiency syndrome	0.00148	0.0162	CbGeAlD
Triflupromazine—BCHE—vagina—acquired immunodeficiency syndrome	0.00147	0.0161	CbGeAlD
Triflupromazine—DRD2—nervous system—acquired immunodeficiency syndrome	0.00142	0.0155	CbGeAlD
Triflupromazine—BCHE—lung—acquired immunodeficiency syndrome	0.00139	0.0152	CbGeAlD
Triflupromazine—DRD2—central nervous system—acquired immunodeficiency syndrome	0.00137	0.015	CbGeAlD
Triflupromazine—CHRM1—brain—acquired immunodeficiency syndrome	0.00135	0.0148	CbGeAlD
Triflupromazine—HTR2B—brain—acquired immunodeficiency syndrome	0.00134	0.0147	CbGeAlD
Triflupromazine—HTR2B—lymph node—acquired immunodeficiency syndrome	0.0013	0.0142	CbGeAlD
Triflupromazine—BCHE—nervous system—acquired immunodeficiency syndrome	0.00129	0.0141	CbGeAlD
Triflupromazine—BCHE—central nervous system—acquired immunodeficiency syndrome	0.00124	0.0136	CbGeAlD
Triflupromazine—ABCB1—retina—acquired immunodeficiency syndrome	0.00113	0.0124	CbGeAlD
Triflupromazine—DRD2—brain—acquired immunodeficiency syndrome	0.00109	0.0119	CbGeAlD
Triflupromazine—BCHE—brain—acquired immunodeficiency syndrome	0.000986	0.0108	CbGeAlD
Triflupromazine—BCHE—lymph node—acquired immunodeficiency syndrome	0.000953	0.0104	CbGeAlD
Triflupromazine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000805	0.00879	CbGeAlD
Triflupromazine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000795	0.00869	CbGeAlD
Triflupromazine—ABCB1—blood—acquired immunodeficiency syndrome	0.000757	0.00828	CbGeAlD
Triflupromazine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000733	0.00801	CbGeAlD
Triflupromazine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.00073	0.00797	CbGeAlD
Triflupromazine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000702	0.00767	CbGeAlD
Triflupromazine—ABCB1—lung—acquired immunodeficiency syndrome	0.000664	0.00726	CbGeAlD
Triflupromazine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000615	0.00672	CbGeAlD
Triflupromazine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000592	0.00647	CbGeAlD
Triflupromazine—ABCB1—brain—acquired immunodeficiency syndrome	0.00047	0.00514	CbGeAlD
Triflupromazine—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000454	0.00496	CbGeAlD
Triflupromazine—Acepromazine—ALB—acquired immunodeficiency syndrome	0.000178	0.237	CrCbGaD
Triflupromazine—Thioproperazine—ALB—acquired immunodeficiency syndrome	0.000174	0.232	CrCbGaD
Triflupromazine—Pipotiazine—ALB—acquired immunodeficiency syndrome	0.000171	0.228	CrCbGaD
Triflupromazine—CHRM2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000166	0.00437	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000165	0.00434	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000164	0.00431	CbGpPWpGaD
Triflupromazine—DRD2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000164	0.00431	CbGpPWpGaD
Triflupromazine—DRD2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000164	0.00431	CbGpPWpGaD
Triflupromazine—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000162	0.00425	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00016	0.0042	CbGpPWpGaD
Triflupromazine—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000158	0.00416	CbGpPWpGaD
Triflupromazine—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000158	0.00416	CbGpPWpGaD
Triflupromazine—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000158	0.00416	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000157	0.00411	CbGpPWpGaD
Triflupromazine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000156	0.00411	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000155	0.00406	CbGpPWpGaD
Triflupromazine—DRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000155	0.00406	CbGpPWpGaD
Triflupromazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000153	0.00403	CbGpPWpGaD
Triflupromazine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000152	0.004	CbGpPWpGaD
Triflupromazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00015	0.00394	CbGpPWpGaD
Triflupromazine—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000149	0.00391	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000148	0.00389	CbGpPWpGaD
Triflupromazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000148	0.00389	CbGpPWpGaD
Triflupromazine—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000147	0.00386	CbGpPWpGaD
Triflupromazine—HTR2B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000146	0.00385	CbGpPWpGaD
Triflupromazine—DRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00014	0.00367	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000139	0.00366	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000139	0.00366	CbGpPWpGaD
Triflupromazine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000139	0.00366	CbGpPWpGaD
Triflupromazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000139	0.00364	CbGpPWpGaD
Triflupromazine—DRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000138	0.00363	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000136	0.00358	CbGpPWpGaD
Triflupromazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000136	0.00356	CbGpPWpGaD
Triflupromazine—Clomipramine—ALB—acquired immunodeficiency syndrome	0.000135	0.18	CrCbGaD
Triflupromazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000134	0.00352	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000133	0.00349	CbGpPWpGaD
Triflupromazine—DRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000131	0.00345	CbGpPWpGaD
Triflupromazine—DRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000131	0.00345	CbGpPWpGaD
Triflupromazine—DRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000131	0.00345	CbGpPWpGaD
Triflupromazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00013	0.00342	CbGpPWpGaD
Triflupromazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00013	0.00342	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000128	0.00337	CbGpPWpGaD
Triflupromazine—BCHE—Metabolism—TAT—acquired immunodeficiency syndrome	0.000128	0.00336	CbGpPWpGaD
Triflupromazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000127	0.00335	CbGpPWpGaD
Triflupromazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000127	0.00335	CbGpPWpGaD
Triflupromazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000126	0.00331	CbGpPWpGaD
Triflupromazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000126	0.00331	CbGpPWpGaD
Triflupromazine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000125	0.0033	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000125	0.00329	CbGpPWpGaD
Triflupromazine—DRD2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000125	0.00328	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000123	0.00323	CbGpPWpGaD
Triflupromazine—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.00012	0.00316	CbGpPWpGaD
Triflupromazine—DRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000118	0.00311	CbGpPWpGaD
Triflupromazine—DRD2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000117	0.00307	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000116	0.00305	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000114	0.003	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000113	0.00296	CbGpPWpGaD
Triflupromazine—DRD2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000112	0.00295	CbGpPWpGaD
Triflupromazine—BCHE—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000109	0.00286	CbGpPWpGaD
Triflupromazine—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000108	0.00285	CbGpPWpGaD
Triflupromazine—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	0.000108	0.00284	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000106	0.00279	CbGpPWpGaD
Triflupromazine—DRD2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000106	0.00277	CbGpPWpGaD
Triflupromazine—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000104	0.00274	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000103	0.00271	CbGpPWpGaD
Triflupromazine—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000102	0.00268	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000102	0.00268	CbGpPWpGaD
Triflupromazine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000101	0.00265	CbGpPWpGaD
Triflupromazine—DRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	9.99e-05	0.00263	CbGpPWpGaD
Triflupromazine—DRD2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.92e-05	0.00261	CbGpPWpGaD
Triflupromazine—DRD2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.92e-05	0.00261	CbGpPWpGaD
Triflupromazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.91e-05	0.0026	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.71e-05	0.00255	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.71e-05	0.00255	CbGpPWpGaD
Triflupromazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.7e-05	0.00255	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.69e-05	0.00255	CbGpPWpGaD
Triflupromazine—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	9.61e-05	0.00252	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	9.58e-05	0.00252	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	9.58e-05	0.00252	CbGpPWpGaD
Triflupromazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	9.57e-05	0.00252	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	9.55e-05	0.00251	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.48e-05	0.00249	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.45e-05	0.00248	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	9.36e-05	0.00246	CbGpPWpGaD
Triflupromazine—Chlorpromazine—ALB—acquired immunodeficiency syndrome	9.26e-05	0.124	CrCbGaD
Triflupromazine—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.25e-05	0.00243	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.13e-05	0.0024	CbGpPWpGaD
Triflupromazine—DRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	9e-05	0.00237	CbGpPWpGaD
Triflupromazine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.93e-05	0.00235	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.76e-05	0.0023	CbGpPWpGaD
Triflupromazine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.74e-05	0.0023	CbGpPWpGaD
Triflupromazine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	8.62e-05	0.00227	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.58e-05	0.00225	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	8.47e-05	0.00222	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.41e-05	0.00221	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.37e-05	0.0022	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.04e-05	0.00211	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.04e-05	0.00211	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.93e-05	0.00208	CbGpPWpGaD
Triflupromazine—DRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.9e-05	0.00208	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.87e-05	0.00207	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.87e-05	0.00207	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.6e-05	0.002	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.58e-05	0.00199	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.58e-05	0.00199	CbGpPWpGaD
Triflupromazine—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.55e-05	0.00198	CbGpPWpGaD
Triflupromazine—DRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.42e-05	0.00195	CbGpPWpGaD
Triflupromazine—DRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.42e-05	0.00195	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.39e-05	0.00194	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.29e-05	0.00192	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.27e-05	0.00191	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.17e-05	0.00188	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.15e-05	0.00188	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.15e-05	0.00188	CbGpPWpGaD
Triflupromazine—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	7e-05	0.00184	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.86e-05	0.0018	CbGpPWpGaD
Triflupromazine—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.8e-05	0.00179	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.74e-05	0.00177	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.74e-05	0.00177	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.65e-05	0.00175	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	6.57e-05	0.00173	CbGpPWpGaD
Triflupromazine—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	6.34e-05	0.00167	CbGpPWpGaD
Triflupromazine—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	6.23e-05	0.00164	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.99e-05	0.00157	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.99e-05	0.00157	CbGpPWpGaD
Triflupromazine—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.96e-05	0.00157	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.9e-05	0.00155	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.86e-05	0.00154	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.84e-05	0.00153	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.78e-05	0.00152	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.76e-05	0.00151	CbGpPWpGaD
Triflupromazine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	5.75e-05	0.00151	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.72e-05	0.0015	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.72e-05	0.0015	CbGpPWpGaD
Triflupromazine—DRD1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	5.72e-05	0.0015	CbGpPWpGaD
Triflupromazine—DRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.65e-05	0.00148	CbGpPWpGaD
Triflupromazine—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.61e-05	0.00147	CbGpPWpGaD
Triflupromazine—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.61e-05	0.00147	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.6e-05	0.00147	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.6e-05	0.00147	CbGpPWpGaD
Triflupromazine—DRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.56e-05	0.00146	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.53e-05	0.00145	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.53e-05	0.00145	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.49e-05	0.00144	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.49e-05	0.00144	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.44e-05	0.00143	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.42e-05	0.00142	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.42e-05	0.00142	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.41e-05	0.00142	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.4e-05	0.00142	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.36e-05	0.00141	CbGpPWpGaD
Triflupromazine—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	5.3e-05	0.00139	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.3e-05	0.00139	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.23e-05	0.00137	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.18e-05	0.00136	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.13e-05	0.00135	CbGpPWpGaD
Triflupromazine—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	5.11e-05	0.00134	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.09e-05	0.00134	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.09e-05	0.00134	CbGpPWpGaD
Triflupromazine—DRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.09e-05	0.00134	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.07e-05	0.00133	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.05e-05	0.00133	CbGpPWpGaD
Triflupromazine—BCHE—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5e-05	0.00131	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5e-05	0.00131	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.98e-05	0.00131	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.98e-05	0.00131	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.97e-05	0.00131	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.92e-05	0.00129	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.92e-05	0.00129	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.9e-05	0.00129	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.68e-05	0.00123	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.62e-05	0.00121	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.49e-05	0.00118	CbGpPWpGaD
Triflupromazine—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	4.32e-05	0.00114	CbGpPWpGaD
Triflupromazine—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.26e-05	0.00112	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.24e-05	0.00111	CbGpPWpGaD
Triflupromazine—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	4.23e-05	0.00111	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.22e-05	0.00111	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.22e-05	0.00111	CbGpPWpGaD
Triflupromazine—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.2e-05	0.0011	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.17e-05	0.0011	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.12e-05	0.00108	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.11e-05	0.00108	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.06e-05	0.00107	CbGpPWpGaD
Triflupromazine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	4.01e-05	0.00105	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.98e-05	0.00105	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.98e-05	0.00105	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.87e-05	0.00102	CbGpPWpGaD
Triflupromazine—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.84e-05	0.00101	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.81e-05	0.001	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.79e-05	0.000996	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.76e-05	0.000988	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.74e-05	0.000983	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.73e-05	0.000981	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.71e-05	0.000975	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.69e-05	0.000968	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.54e-05	0.000929	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.49e-05	0.000917	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.46e-05	0.00091	CbGpPWpGaD
Triflupromazine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	3.45e-05	0.000907	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.42e-05	0.000898	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.41e-05	0.000897	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.37e-05	0.000886	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.21e-05	0.000844	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.2e-05	0.00084	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.16e-05	0.000832	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.13e-05	0.000823	CbGpPWpGaD
Triflupromazine—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.12e-05	0.000819	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.09e-05	0.000812	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.03e-05	0.000796	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.01e-05	0.00079	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.01e-05	0.00079	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.98e-05	0.000784	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.94e-05	0.000773	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.94e-05	0.000773	CbGpPWpGaD
Triflupromazine—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.94e-05	0.000773	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.91e-05	0.000763	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.91e-05	0.000763	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.89e-05	0.000761	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.83e-05	0.000744	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.73e-05	0.000717	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.67e-05	0.000702	CbGpPWpGaD
Triflupromazine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	2.32e-05	0.00061	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.29e-05	0.000601	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.25e-05	0.000592	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.24e-05	0.000588	CbGpPWpGaD
Triflupromazine—BCHE—Metabolism—ALB—acquired immunodeficiency syndrome	2.23e-05	0.000586	CbGpPWpGaD
Triflupromazine—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.22e-05	0.000583	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.21e-05	0.000581	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.21e-05	0.00058	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.18e-05	0.000572	CbGpPWpGaD
Triflupromazine—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.17e-05	0.000571	CbGpPWpGaD
Triflupromazine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.14e-05	0.000564	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.06e-05	0.000542	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.02e-05	0.00053	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.02e-05	0.00053	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.99e-05	0.000523	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.97e-05	0.000518	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.95e-05	0.000512	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.67e-05	0.00044	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.66e-05	0.000437	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.58e-05	0.000414	CbGpPWpGaD
Triflupromazine—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.57e-05	0.000412	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.19e-05	0.000313	CbGpPWpGaD
Triflupromazine—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.18e-05	0.000311	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.17e-05	0.000306	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.16e-05	0.000305	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.15e-05	0.000302	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.14e-05	0.000301	CbGpPWpGaD
Triflupromazine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.09e-05	0.000286	CbGpPWpGaD
Triflupromazine—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.83e-06	0.000258	CbGpPWpGaD
Triflupromazine—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.27e-06	0.000244	CbGpPWpGaD
Triflupromazine—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7e-06	0.000184	CbGpPWpGaD
Triflupromazine—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.85e-06	0.00018	CbGpPWpGaD
Triflupromazine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.76e-06	0.000178	CbGpPWpGaD
